Tetrahydropyridoindole derivatives
AssigneeActelion Pharmaceuticals Ltd.
InventorsAnja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
Life of this patent
Estimating the term…
Abstract
The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.
Claims15
A compound selected from the group consisting of tetrahydropyridoindole derivatives of the general Formula (I)
- wherein
- R1, R2, R3 and R4 independently represent hydrogen, C1-C5-alkyl, C1-C5-alkoxy, halogen, nitro, cyano or formyl;
- and
- R5 represents C0-C5-alkyl-carbonyl, C2-C5-alkenyl-carbonyl, C1-C5-alkoxy-carbonyl, C1-C5-alkyl, C1-C5-alkyl-carbamoyl, aryl-C1-C5-alkyl, aryl-carbonyl, aryl-C1-C5-alkyl-carbonyl, aryl-C1-C5-alkoxy-carbonyl, aryl-carbamoyl, aryl-thiocarbamoyl, aryl-C1-C5-alkyl-carbamoyl, aryl-C1-C5-alkyl-thiocarbamoyl, cycloalkyl-carbonyl, cycloalkyl-C1-C5-alkyl-carbonyl, cycloalkyl-C1-C5-alkoxy-carbonyl, cycloalkyl-carbamoyl, heteroaryl-C1-C5-alkyl, heteroaryl-carbonyl, heteroaryl-C1-C5-alkyl-carbonyl or heteroaryl-C1-C5-alkoxy-carbonyl;
- with the proviso that when R1, R2, R3 and R4 represent hydrogen, R5 is not an ethoxy-carbonyl group or a tert.-butoxycarbonyl group;
- and optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates, meso forms, and salts thereof.
A compound for use as a medicament, wherein said compound is selected from the group consisting of tetrahydropyridoindole derivatives of the following general Formula (II):
- wherein
- R6, R7, R8 and R9 independently represent hydrogen, C1-C5-alkyl, C1-C5-alkoxy, halogen, nitro, cyano or formyl;
- and
- R10 represents C0-C5-alkyl-carbonyl, C2-C5-alkenyl-carbonyl, C1-C5-alkoxy-carbonyl, C1-C5-alkyl, C1-C5-alkyl-carbamoyl, aryl-C1-C5-alkyl, aryl-carbonyl, aryl-C1-C5-alkyl-carbonyl, aryl-C1-C5-alkoxy-carbonyl, aryl-carbamoyl, aryl-thiocarbamoyl, aryl-C1-C5-alkyl-carbamoyl, aryl-C1-C5-alkyl-thiocarbamoyl, cycloalkyl-carbonyl, cycloalkyl-C1-C5-alkyl-carbonyl, cycloalkyl-C1-C5-alkoxy-carbonyl, cycloalkyl-carbamoyl, heteroaryl-C1-C5-alkyl, heteroaryl-carbonyl, heteroaryl-C1-C5-alkyl-carbonyl or heteroaryl-C1-C5-alkoxy-carbonyl;
- and optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates, meso forms, and pharmaceutically acceptable salts thereof.
A pharmaceutical composition comprising at least one compound according to any one of 1, 10, 12 and 13 and an inert carrier material and/or adjuvant.
Dependencies are inferred from the claim text.